BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
OPDIVO (nivolumab) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2014.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO (nivolumab) is a monoclonal antibody that blocks programmed death receptor-1 (PD-1), a key immune checkpoint, to reinvigorate anti-tumor immunity. It is approved for multiple cancer indications including melanoma, non-small cell lung cancer, renal cell carcinoma, and others. The drug works by unleashing T-cell mediated tumor destruction through checkpoint inhibition.
$0.051BPart D
PeakStable
Peak-stage franchise with established market presence supporting mature brand and commercial excellence teams at Bristol Myers Squibb.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Started Nov 2026
30 enrolled
Untreated MelanomaUnresectable MelanomaMetastatic Melanoma
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Started Jun 2026
68 enrolled
Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastoma+1 more
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Started Jun 2026
26 enrolled
Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Started Jun 2026
120 enrolled
Melanoma
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Started May 2026
170 enrolled
Advanced Microsatellite Stable Colorectal Cancer
Worked on OPDIVO at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.